Artiva Biotherapeutics, Inc. (ARTV) Stock Statistics & Valuation Metrics

Artiva Biotherapeutics, Inc. has a market cap or net worth of $152.75M. The enterprise value is $135.93M.

Artiva Biotherapeutics, Inc. has 24,716,673 shares outstanding. The number of shares has decreased by -2.65% in one year.

Artiva Biotherapeutics, Inc.’s return on equity (ROE) is -0.76 and return on invested capital (ROIC) is -74.94%.

The current PE Ratio of Artiva Biotherapeutics, Inc. is ―. Artiva Biotherapeutics, Inc.’s PEG ratio is 0.04.

In the last 12 months, Artiva Biotherapeutics, Inc. had revenue of 0.00 and earned -83.86M in profits. Earnings per share was -3.43.

In the last 12 months, operating cash flow was -76.75M and capital expenditures -2.59M, giving a free cash flow of -79.34M billion.

Artiva Biotherapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Artiva Biotherapeutics, Inc. upcoming earnings date is May 7, 2026, After Close (Confirmed).

Artiva Biotherapeutics, Inc. as a current ratio of 8.61, with Debt / Equity ratio of 9.95%

In the past 12 months, Artiva Biotherapeutics, Inc. has paid 0.00 in taxes.

Artiva Biotherapeutics, Inc. EV to EBITDA ratio is -1.01, with an EV/FCF ratio of -1.12.

Artiva Biotherapeutics, Inc. has $108.01M in cash and marketable securities with $10.94M in debt, giving a net cash position of $97.07M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Artiva Biotherapeutics, Inc. is $17.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy